Business · Markets · 56 mins ago
Identifai Genetics lists on the ASX after raising $10 million
Identifai Genetics, an Israel-based company, began trading on the Australian Securities Exchange after raising $10 million.
Its main product, Windrose, is a prenatal genetic test that uses a blood sample from the pregnant person.
The company says the test can assess fetal risk for conditions linked to more than 280 genes, including disorders that standard prenatal screening may not cover comprehensively.
Windrose is designed for use from about nine weeks of pregnancy and combines whole-genome sequencing, bioinformatics and artificial intelligence.
Identifai says some conditions it screens for may be treatable during pregnancy, and it hopes to launch the test in the United States in the coming months through a laboratory approval route.
The company’s shares opened 15% above their listing price.
Identifai Genetics began trading on the Australian Securities Exchange after raising $10 million.
The Israel-based company debuted at a 15% premium to its listing price, according to Stockhead.
It plans to use the funds to commercialise Windrose, an AI-driven prenatal genetic testing platform.
Windrose uses a maternal blood sample from about nine weeks of pregnancy to assess fetal risk for conditions linked to more than 280 genes.
The company hopes to launch Windrose in the United States in the coming months through a CLIA lab-approved route.
- Who
- Identifai Genetics, an Israel-based company.
- What
- It listed on the ASX after raising $10 million to commercialise its Windrose prenatal genetic testing platform.
- When
- October 13, 2026, according to the article’s publication date and its description of the listing as happening that day.
- Where
- On the Australian Securities Exchange (ASX). The company is based in Israel.
- Why
- To fund commercialisation of Windrose, its AI-driven prenatal genetic testing platform.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Funds raised
- $10 million
- Listing venue
- Australian Securities Exchange (ASX)
- Debut premium
- 15%
- Flagship product
- Windrose
- Genes assessed
- More than 280 clinically actionable genes
What people are saying
Our ambition is to make earlier clinically relevant genetic information more accessible through a single maternal blood sample
Sources
Related news
No details available about retirement changes
Perth rental vacancy rate falls to a two-year low
ASX falls as China lithium supply news weighs on miners and oil prices rise
Brokers see potential gains for NexGen Energy and Viva Energy shares
Delorean signs non-binding $20m financing agreement with Westpac
IMF oil-price scenario could push Australian petrol up 30 cents a litre
Evolution Mining compared with Northern Star Resources for investors
IMF expects Australia’s unemployment rate to rise to 4.7% in 2027
Stelar begins 3,500-metre tungsten drilling in Northern Territory
Shell says Australia’s gas reserve plan risks market failure
Astral finds high-grade gold beneath Theia and extends mineralisation south
